^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IDH305

    i
    Other names: IDH305, IDH-305, IDH 305
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    IDH1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations (clinicaltrials.gov)
    P1, N=166, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date • Metastases
    |
    IDH1 R132
    |
    IDH305
    over2years
    Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis. (PubMed, Open Med (Wars))
    However, current targeted inhibitors of IDH1 mutation (AG120 and IDH305) reversed these effects caused by IDH1 mutation. The in vivo experiment showed that IDH1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to erastin-induced ferroptosis. This study indicated that IDH1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to erastin-induced ferroptosis.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH1 R132C • IDH1 R132
    |
    Tibsovo (ivosidenib) • erastin • IDH305
    over2years
    A phase 1 study of IDH305 in patients with IDH1-mutant acute myeloid leukemia or myelodysplastic syndrome. (PubMed, J Cancer Res Clin Oncol)
    Due to potentially narrow therapeutic window, the study was prematurely halted and recommended phase 2 dose could not be declared.
    P1 data • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH1 R132
    |
    IDH305